ZGN-440 sterile diluent

DRUG3 trials

Sponsors

Zafgen, Inc.

Conditions

CraniopharyngiomaHypothalamic InjuryObesityOver-weightPrader-Willi Syndrome

Phase 1

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

CompletedNCT01507077

Zafgen, Inc.Obesity

Start: 2011-12-31End: 2012-03-31Updated: 2012-07-18

Phase 2

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

CompletedNCT01818921

Zafgen, Inc.Obesity, Over-weight, Prader-Willi Syndrome

Start: 2013-06-30End: 2013-11-30Updated: 2016-07-18

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

CompletedNCT02063295

Zafgen, Inc.Craniopharyngioma, Hypothalamic Injury, Obesity +1

Start: 2014-04-30End: 2014-11-30Updated: 2016-07-18